

REMARKS

Claim status. Claims 2 to 13 and 25 are pending in this application. Claims 1 and 14 to 24 are canceled hereby as directed to non-elected subject matter, and Applicants reserve the right to file divisional applications thereon. Claim 6 was canceled as redundant to Claim 2. Claims 3 and 25 are amended to clarify their dependency from Claim 2 and proper inclusion in the elected group under the restriction requirement, as explained further below. No claim has been added.

Election under Restriction Requirement. The Applicants hereby elect Group II identified in the Office Action, Claims 2 and 6 to 13, with traverse. The Applicants further elect the species of SEQ ID NO: 136 linked to SEQ ID NO: 2. This species corresponds to the claims as follows:

- o the compound of Claim 2 wherein a is 1, b is 0, X' is (L')_c-P', c is 0, P' is SEQ ID NO: 136 and F' is SEQ ID NO: 2;
- o the compound of Claim 3 wherein X' is (L')_c-P', c is 0, P' is SEQ ID NO: 136 and F' is SEQ ID NO: 2;
- o the compound of Claim 4 wherein c is 0, P' is SEQ ID NO: 136 and F' is SEQ ID NO: 2;
- o the compound of Claim 25 comprising SEQ ID NO: 136.

Because SEQ ID NO: 2 is an IgG1 Fc domain sequence, the elected species is a dimer.


Traverse to Restriction Requirement. Claims 3, 4, 5, and 25 should be considered together with Claim 2. Claim 25 in its previous form overlapped Claim 2, as when X' comprised one of the sequences recited in Claim 25. As amended, Claim 25 becomes a subset of Claim 2.¹ Claim 3 is directed toward a subset of the class of compounds encompassed by Claim 2-i.e., wherein a is 1 and b is 0 and vice-versa. Claim 3 uses the same substituents (X', L', F', etc.) as Claim 2. Likewise claims 4 and 5 use substituents encompassed by Claim 2. For these reasons, a search of Claim 2 would necessarily overlap a search of Claims 3, 4, 5, and 25 and impose no undue burden when such claims are examined together with Claim 2. This point is demonstrated by the inclusion of the elected species within Claims 2, 3, 4, and 25.

Conclusion. In view of the foregoing amendments and remarks, the Applicants respectfully

¹ Applicants reserve the right to pursue Claim 25 in its original form in a divisional application.

request reconsideration of the restriction requirement, entry of all amendments, and allowance of all claims.

Respectfully submitted,



Timothy J. Gaul
Attorney for Applicant
Registration No.: 33,111
Phone: (805) 447-2688
Date: January 30, 2003

Please send all future correspondence to:

US Patent Operations/ T.J.G.
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

VERSION SHOWING CHANGES

3. The composition of matter of Claim 42 of the formulae

X¹-P¹

or

F¹-X².

25. ~~AThe~~ composition of matter of Claim 2 comprising an amino acid sequence selected from SEQ ID NOS: 132 to 137.